1-6 of 272 Activities
In this CME Outfitters live Q&A, expert faculty will answer questions about the multifaceted impact of GLP-1 RA therapies on glycemic control, CV health, weight management, renal health, liver health, and overall T2D complication risk.
This fast-paced and highly interactive livestream CaseWise™ symposium from CME Outfitters will bring real-world clinical decision-making to life. Through dynamic patient cases, learners will compare their treatment choices to those of leading experts, peers in the room, providers in the community, patients themselves, and even AI-based insights. Learners will see how evidence translates into practice, what doesn’t, and why. Designed to challenge assumptions and sharpen strategy, this immersive format empowers clinicians to immediately apply the latest IL-23 inhibitor data, enhance communication and shared decision-making, and deliver truly patient-centered IBD care.
Primary Immunodeficiency (PI) disorders are a group of more than 180 inherited disorders, of the approximately 550 inborn errors of immunity (IEIs), that predispose affected patients to a variety of bacterial, viral, and fungal infections. Infections may be more prolonged or severe in patients with PI when compared with immunocompetent patients infected with the same organisms.1,2 Early detection of PI and appropriate short- and long-term management of patients with these conditions have been shown to significantly reduce morbidity and mortality.3,4 However, on average it takes 9-15 years to achieve a diagnosis. Pediatric clinicians should be familiar with the history and clinical characteristics that indicate a potential PI and warrant an initial evaluation and/or a referral to an immunologist for evaluation.
It is estimated that between one in 500 to one in 1,200 people in the United States have a PI, amounting to approximately 250,000 cases.5,6 However, there may be as many as 500,000 undiagnosed additional cases, as evidence suggests that these diagnoses often go unrecognized.7
This fourth Snack in the series features experts Naim Alkhouri, MD, and Monica Tincopa, MD, MSc, who together provide practical insights and forward-looking perspectives on where MASH management is headed and what to anticipate in clinical practice.
This CME Outfitters program will incorporate an interactive decision-tree tool to help clinicians apply evidence-based lipid-lowering strategies in real time. Decision trees transform complex guidelines into practical, case-based pathways that clarify when to adjust therapy and integrate emerging treatments. By engaging clinicians in realistic scenarios, this format addresses inertia, corrects misconceptions, and builds confidence in individualized lipid management to improve ASCVD outcomes.
In this CME Outfitters Journal Club, expert faculty will provide their perspectives on key aspects of the FDA’s Opioid Analgesic REMS Education Blueprint for Health Care Providers Involved in the Treatment and Monitoring of Patients with Pain. Focus will be on bringing the concepts from this document into daily practice including strategies for identifying the physiologic biopsychosocial factors that influence pain, utilizing pain assessment tools that reinforce approaches to the appropriate management of pain, implementing strategies from the 2022 CDC Guideline for Prescribing Opioids into the development of safe and effective pain management plans, and other valuable skills for improving the treatment of patients suffering from chronic pain.
In this CME Outfitters Clinical Navigator, expert faculty will discuss strategies for identifying the physiologic biopsychosocial factors that influence pain, utilizing pain assessment tools that reinforce approaches to the appropriate management of pain, implementing strategies from the 2022 CDC Guideline for Prescribing Opioids into the development of safe and effective pain management plans, and other valuable skills for improving the treatment of patients suffering from chronic pain.